Jio Platforms Limited debuted on the stock market on October 28, 2026, following its ₹30,213 crore initial public offering (IPO).
The shares listed at ₹1,358 apiece on both the NSE and BSE, against an issue price of ₹1,119, delivering a listing premium of 21.36%. The IPO received an overall subscription of 22.19 times during its three-day bidding period from October 21 to October 23, 2026.
The listing brings Reliance Industries-backed Jio Platforms into the listed market, allowing investors to trade shares in the company on the NSE and BSE.
[October 23, 2026, 7:00 PM]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
70.55x |
|
Non-Institutional Investors (NIIs) |
14.00x |
|
Retail Individual Investors (RIIs) |
2.72x |
|
Employees |
2.93x |
|
Shareholders |
7.60x |
|
Total |
22.19x |
The company intends to utilise the net proceeds from the fresh issue towards:
Founded in 2019, Jio Platforms Limited is a technology company focused on digital connectivity and services in India. Through its subsidiary, Reliance Jio Infocomm Limited (RJIL), it provides mobile and fixed broadband connectivity and digital offerings across entertainment, cloud computing, smart homes, gaming, enterprise solutions and AI-powered applications. As of March 31, 2026, RJIL had a customer base of 524.4 million.
The company has an integrated technology ecosystem spanning network infrastructure, devices, software, operating systems and digital applications. This in-house framework supports the development and deployment of 4G, 5G, cloud and AI technologies, while reducing reliance on external vendors and enabling innovation across its digital services.
|
Particulars |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
FY24 (in ₹ crore) |
|
Revenue from operations |
1,46,885.00 |
1,28,218.00 |
1,09,558.10 |
|
EBITDA |
76,255.40 |
64,170.00 |
54,958.70 |
|
Profit After Tax (PAT) |
30,049.70 |
26,120.30 |
21,423.20 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.